Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

serum institute of india pvt ltd. - hepatitis b surface antigene - suspension for injection - 10mcg/dose

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

serum institute of india pvt ltd. - hepatitis b surface antigene - suspension for injection - 20mcg/dose

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

serum institute of india pvt ltd. - hepatitis b surface antigene - suspension for injection - 20mcg/dose

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

serum institute of india pvt ltd. - hepatitis b surface antigene - suspension for injection - 20mcg/dose

Malta - English - Medicines Authority

glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - haemophilus influenzae, b, tetanus toxoid - powder and solvent for solution for infusion - haemophilus influenzae b 10 µg tetanus toxoid 25 µg - vaccines

European Union - English - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningococcal - vaccines - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y.the use of this vaccine should be in accordance with available official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - meningococcal polysaccharide group w135, quantity: 10 microgram; meningococcal polysaccharide group c, quantity: 10 microgram; meningococcal polysaccharide group a, quantity: 10 microgram; meningococcal polysaccharide group y, quantity: 10 microgram - injection, solution - excipient ingredients: sodium acetate; tetanus toxoid; sodium chloride; water for injections - menquadfi is indicated for active immunisation for the prevention of invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w and y.,the use of menquadfi should be in accordance with official recommendations.

Canada - English - Health Canada

glaxosmithkline inc - pneumococcal polysaccharide serotype 1 conjugated to protein d carrier protein; pneumococcal polysaccharide serotype 4 conjugated to protein d carrier protein; pneumococcal polysaccharide serotype 5 conjugated to protein d carrier protein; pneumococcal polysaccharide serotype 6b conjugated to protein d carrier protein; pneumococcal polysaccharide serotype 7f conjugated to protein d carrier protein; pneumococcal polysaccharide serotype 9v conjugated to protein d carrier protein; pneumococcal polysaccharide serotype 14 conjugated to protein d carrier protein; pneumococcal polysacc. serot. 18c conjug. to tetanus toxoid carrier prot.; pneumococcal polysaccharid serot. 19f conjug. to diphtheria toxoid carrier prot.; pneumococcal polysaccharide serotype 23f conjugated to protein d carrier protein - suspension - 1mcg; 3mcg; 1mcg; 1mcg; 1mcg; 1mcg; 1mcg; 3mcg; 3mcg; 1mcg - pneumococcal polysaccharide serotype 1 conjugated to protein d carrier protein 1mcg; pneumococcal polysaccharide serotype 4 conjugated to protein d carrier protein 3mcg; pneumococcal polysaccharide serotype 5 conjugated to protein d carrier protein 1mcg; pneumococcal polysaccharide serotype 6b conjugated to protein d carrier protein 1mcg; pneumococcal polysaccharide serotype 7f conjugated to protein d carrier protein 1mcg; pneumococcal polysaccharide serotype 9v conjugated to protein d carrier protein 1mcg; pneumococcal polysaccharide serotype 14 conjugated to protein d carrier protein 1mcg; pneumococcal polysacc. serot. 18c conjug. to tetanus toxoid carrier prot. 3mcg; pneumococcal polysaccharid serot. 19f conjug. to diphtheria toxoid carrier prot. 3mcg; pneumococcal polysaccharide serotype 23f conjugated to protein d carrier protein 1mcg - vaccines

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - haemophilus influenza type b polyribose ribitol phosphate,meningococcal polysaccharide group c,tetanus toxoid -

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - conjugate of haemophilus influenzae type b capsular polysaccharide (polyribosylribitol phosphate) and tetanus; conjugate of neisseria meningitides c capsular polysaccharide and tetanus toxoid (mean tt/ps ratio :1) - powder and solvent for solution for injection - 0.5 millilitre(s) - hemophilus influenzae b, combinations with meningococcus c, conjugated